ACTIVE HALF-LIFE
2 days
CLASSIFICATION
Non-steroidal Aromatase Inhibitor
DOSAGE
0.5 - 2.5 mg/day
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Euro-Pharmacies - US
LAB TEST
See Document
WAREHOUSE
USA Warehouse 3
SUBSTANCE
Letrozole
Introducing Letrozolexin, a powerful non-steroidal aromatase inhibitor expertly designed to inhibit estrogen synthesis and offer remarkable antineoplastic benefits. As a third-generation aromatase inhibitor, Letrozolexin uniquely and reversibly blocks aromatase, a crucial enzyme in estrogen production, potentially stifling the growth of estrogen-dependent breast cancer cells.
Aromatase, a cytochrome P-450 enzyme, plays a pivotal role in converting androstenedione and testosterone into estrone and estradiol?key estrogens in the body. By competitively binding to the enzyme's heme group, Letrozolexin effectively halts this conversion while preserving the synthesis of essential mineralocorticoids and corticosteroids. Unlike tamoxifen, which binds to estrogen receptors to exert its anti-estrogenic effects, Letrozolexin targets the source of estrogen production itself.
Approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic hormone receptor-positive breast cancer, Letrozolexin is particularly beneficial for postmenopausal women. While it is generally well-tolerated, some may experience side effects related to decreased estrogen levels. To address potential long-term risks, such as osteoporosis, healthcare providers often prescribe Letrozolexin alongside medications like Fosamax.
Studies suggest that Letrozolexin can reduce estrogen levels by an impressive 98%, all while boosting testosterone levels. These anti-estrogen properties have made it a popular choice among athletes and bodybuilders during steroid cycles, helping to combat water retention and reduce the risk of gynecomastia associated with certain anabolic steroids. However, it is important to note that exceeding 2.5 mg per day may temporarily affect libido, and long-term use above 5 mg daily could lead to kidney complications.
Moreover, Letrozolexin has shown potential in delaying the fusion of growth plates in adolescents, which could enhance the effectiveness of growth hormone therapy, making it a viable option for treating children and adolescents with short stature.